BioSpace News Archive

- CAR T-cell therapy manufacturing commenced with Iomab-ACT conditioning and patient treatment scheduled for early Q2:2021 - Clinical proof-of-concept data expected in 2H:2021 from first of its kind trial funded by NIH STTR grant

BetterLife Pharma Inc. , an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, announces an agreement with the laboratory of Dr. Adam L. Halberstadt at the University of California San Diego for TD-0148A preclinical behavioural pharmacology studies.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® technology platform, today announced that it will host a virtual investor event at 1:00 p.m. – 3:00 p.m. ET / 10:00 a.m. – 12:00 p.m.

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric NO for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced that the Company will present two abstracts at the upcoming American Thoracic Society International Conference 2021

Biologic imaging reagents are substances utilized by researchers or by medical practitioners to conduct diagnostic or research based activities.

Joint related issues are mostly recorded in geriatric and old aged peoples. Joint pain is caused due to tearing of synovial fluid in the joints due to injury or ageing.

In recent months, there is a striking increase in the spread of COVID-19 infection in all worldwide locations.

KB109 demonstrated favorable safety and tolerability profile Kaleido intends to file an Investigational New Drug (IND) application, with the goal of advancing KB109 directly into a pivotal registration program Company to host conference call today at 8:30am ET

Ascentage Pharma has recommended the novel candidate drug olverembatinib (HQP1351) of Guangzhou Healthquest Pharma Co.

Patients with mild-to-moderate Alzheimer’s disease (AD) receiving Leukine experienced significant reversal of cognitive loss and biomarkers of disease progression while taking Leukine Study shows Leukine safe and tolerable and concludes that the innate immune system is a viable target for therapeutic intervention in AD